temozolomide has been researched along with Aura in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 7.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "Temozolomide treatment did not affect TPM plasma concentrations in chronically treated patients." | 6.73 | Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Pace, A; Zarabla, A, 2008) |
| " Temozolomide is a novel second-generation alkylating agent that has shown efficacy for the treatment of high-grade gliomas." | 4.84 | [Glioma therapy up-date]. ( Dalmau, J; de la Fuente, BP; Rosenfeld, M, 2007) |
| " The place of chemotherapy is growing not only for anaplastic oligodendrogliomas, more chemosensitive (particularly when they harbor 1p19q codeletions), but also for glioblastomas patients, which have been shown to benefit from radiotherapy plus concomitant and adjuvant temozolomide." | 4.83 | [Pattern of care of high-grade gliomas]. ( Laigle-Donadey, F; Sanson, M, 2006) |
| "To confirm the hypothesis suggested above, a combined analysis of survival association of antiepileptic drug use at the start of chemoradiotherapy with temozolomide was performed in the pooled patient cohort (n = 1,869) of four contemporary randomized clinical trials in newly diagnosed glioblastoma: AVAGlio (Avastin in Glioblastoma; NCT00943826), CENTRIC (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status; NCT00689221), CORE (Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status; NCT00813943), and Radiation Therapy Oncology Group 0825 (NCT00884741)." | 3.83 | Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. ( Chinot, O; Cloughesy, T; Gilbert, MR; Gorlia, T; Happold, C; Hegi, M; Mehta, MP; Nabors, LB; Perry, JR; Pugh, SL; Reardon, DA; Roth, P; Stupp, R; Weller, M; Wick, W, 2016) |
| "Temozolomide treatment did not affect TPM plasma concentrations in chronically treated patients." | 2.73 | Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy. ( Albani, F; Baruzzi, A; Contin, M; Dinapoli, L; Fabi, A; Jandolo, B; Maschio, M; Pace, A; Zarabla, A, 2008) |
| "Thrombocytopenia was operationalized as a continuous platelet count and a dichotomic variable (cut-off <100." | 1.38 | Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. ( Blasco, J; Bruna, J; Gil, M; Graus, F; Pineda, E; Simó, M; Velasco, R; Verger, E, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Li, F | 1 |
| Zhang, Y | 1 |
| Wang, N | 1 |
| Song, C | 1 |
| Gao, Y | 1 |
| Diao, X | 1 |
| Zhang, H | 1 |
| Loftus, JC | 1 |
| Dhruv, H | 1 |
| Tuncali, S | 1 |
| Kloss, J | 1 |
| Yang, Z | 1 |
| Schumacher, CA | 1 |
| Cao, B | 1 |
| Williams, BO | 1 |
| Eschbacher, JM | 1 |
| Ross, JT | 1 |
| Tran, NL | 1 |
| Happold, C | 1 |
| Gorlia, T | 1 |
| Chinot, O | 1 |
| Gilbert, MR | 1 |
| Nabors, LB | 1 |
| Wick, W | 1 |
| Pugh, SL | 1 |
| Hegi, M | 1 |
| Cloughesy, T | 1 |
| Roth, P | 1 |
| Reardon, DA | 1 |
| Perry, JR | 1 |
| Mehta, MP | 1 |
| Stupp, R | 1 |
| Weller, M | 1 |
| Maschio, M | 2 |
| Albani, F | 1 |
| Jandolo, B | 1 |
| Zarabla, A | 1 |
| Contin, M | 1 |
| Dinapoli, L | 2 |
| Fabi, A | 1 |
| Pace, A | 1 |
| Baruzzi, A | 1 |
| Vidiri, A | 1 |
| Muti, P | 1 |
| Simó, M | 1 |
| Velasco, R | 1 |
| Graus, F | 1 |
| Verger, E | 1 |
| Gil, M | 1 |
| Pineda, E | 1 |
| Blasco, J | 1 |
| Bruna, J | 1 |
| Ngo, L | 1 |
| Nei, M | 1 |
| Glass, J | 1 |
| Laigle-Donadey, F | 1 |
| Sanson, M | 1 |
| de la Fuente, BP | 1 |
| Dalmau, J | 1 |
| Rosenfeld, M | 1 |
2 reviews available for temozolomide and Aura
| Article | Year |
|---|---|
[Pattern of care of high-grade gliomas].
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anticonvulsants; Antineoplastic Agents, Alkylatin | 2006 |
[Glioma therapy up-date].
Topics: Anticoagulants; Anticonvulsants; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothe | 2007 |
1 trial available for temozolomide and Aura
| Article | Year |
|---|---|
Temozolomide treatment does not affect topiramate and oxcarbazepine plasma concentrations in chronically treated patients with brain tumor-related epilepsy.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carbamazepine; Dacarbazi | 2008 |
6 other studies available for temozolomide and Aura
| Article | Year |
|---|---|
Evaluation of the Prognosis of Neuroglioma Based on Dynamic Magnetic Resonance Enhancement.
Topics: Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Chemotherapy, Adjuvant; Contrast Me | 2020 |
TROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.
Topics: Animals; Antineoplastic Agents; Apoptosis; Astrocytes; Cell Line, Tumor; Cell Movement; Cell Prolife | 2013 |
Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemor | 2016 |
Rash in four patients with brain tumor-related epilepsy in monotherapy with oxcarbazepine, during radiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Carbamazepine; Combined Modality Therapy; C | 2010 |
Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; | 2012 |
Temozolomide treatment of refractory epilepsy in a patient with an oligodendroglioma.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Comorbidity; Dacarbazine | 2006 |